Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02993614 · ClinicalTrials.gov registry record
Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors
A clinical trial, sponsored by AstraZeneca.
- Completed
- Registry status
- 99,999
- Enrollment target
NCT02993614: Completed study, sponsored by AstraZeneca.
NCT02993614 is a clinical trial that has completed, run by AstraZeneca. The registered enrollment target is 99,999 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02993614 has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 99,999 participants
- Enrollment target
Study Summary
CVD-REAL is a multinational, observational cohort study in patients with type 2 diabetes mellitus evaluating the comparative effectiveness of initiating treatment with a sodium-glucose co-transporter-2 (SGLT-2) inhibitor versus another glucose-lowering drug. This study will compare the risk of all-cause mortality and clinically relevant cardiovascular (CV) outcomes respectively in patients who are new users of SGLT-2 inhibitors with those who are new users of other glucose-lowering drugs. CVD-REAL is aiming to collect data from approximately 4 million patients overall, from twelve countries across three major world regions.
Primary Outcome
Heart failure events obtained from general practice or hospital records, electronic health records or national health registers; All-cause mortality obtained from linkeage to death national registers
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99,999 participants |
| Start Date | 2017-11-30 |
| Est. Completion | 2020-12-17 |
What the finished NCT02993614 record still lists
NCT02993614 is an observational study that tracks outcomes without assigning an intervention. Its 99,999 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT02993614 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02993614 about?
NCT02993614 is a clinical study titled "Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors". CVD-REAL is a multinational, observational cohort study in patients with type 2 diabetes mellitus evaluating the comparative effectiveness of initiating treatment with a sodium-glucose co-transporter-2 (SGLT-2) inhibitor versus another glucose-lowering drug. This study will compare the risk of all-c...
What is the current status of trial NCT02993614?
This trial is currently completed. The enrollment target is 99,999 participants. The study started on 2017-11-30. Estimated completion is 2020-12-17.
Who is sponsoring clinical trial NCT02993614?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01351545 · 99,999 participants
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- NCT02620852 · 100,000 participants · NA
Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
- NCT03277365 · 100,000 participants · NA
MyGeneRank: A Digital Platform for Next-Generation Genetic Studies
- NCT04281823 · 100,000 participants
DeBakey Cardiovascular Magnetic Resonance Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI